Obesity has implications for chemotherapy dosing and selection of patients for therapy. Autologous hematopoietic stem cell transplant (AutoHCT) improves outcomes for patients with multiple myeloma, but optimal chemotherapy dosing for obese patients is poorly defined. We analyzed the outcomes of 1087 recipients of AutoHCT for myeloma reported to the CIBMTR between 1995 and 2003 who received high-dose melphalan conditioning, with or without total body irradiation (TBI). We categorized patients by body mass index (BMI) as normal, overweight, obese, or severely obese. There was no overall effect of BMI on progression-free survival (PFS), overall survival (OS), progression, or nonrelapse mortality (NRM). In patients receiving melphalan and TBI conditioning, obese and severely obese patients had superior PFS and OS compared with normal and overweight patients, but the clinical significance of this finding is unclear. More obese patients were more likely to receive a reduced dose of melphalan, but there was no evidence that melphalan or TBI dosing variability affected PFS. Therefore, current common strategies of dosing melphalan do not impair outcomes for obese patients, and obesity should not exclude patients from consideration of autologous transplantation. Further research is necessary to optimize dosing of both chemotherapy and radiation in obese patients.
INTRODUCTION
Novel antimyeloma agents have improved outcomes for patients, but the first major advance in myeloma therapy since the 1960s was the demonstration that autologous hematopoietic stem cell transplantation (AutoHCT) improves survival [1, 2] .
AutoHCT involves dose escalation of chemotherapy beyond the myeloablative threshold to a maximumtolerated dose defined by other toxicities. Although multiple myeloma (MM) is the most common indication for AutoHCT [3] , the procedure is not curative. Outcomes remain suboptimal, with significant variability in disease control and treatment-related toxicity.
Obesity is a potential source of variability in treatment outcomes. Obesity may affect outcomes through alterations in chemotherapy dosing and pharmacokinetics [4] ; association with comorbidities or more aggressive disease, worse stage at diagnosis, and poorer response to chemotherapy [5, 6] ; or conversely, as a marker for the absence of cancer cachexia. Because of these overlapping and potentially contradictory effects, understanding the effect of obesity on cancer treatment requires careful study of specific situations and appropriate control for confounding factors. The effect of obesity on outcomes from chemotherapy has been studied in other patient populations [5, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , including patients undergoing hematopoietic stem cell transplantation [18] [19] [20] [21] [22] [23] [24] but not in myeloma patients undergoing AutoHCT.
Conditioning therapy before AutoHCT in MM usually involves a single chemotherapeutic agent, melphalan, given near its maximum tolerated dose, which is based on body surface area (BSA). Although the dose of melphalan is directly related to its toxicity and antineoplastic efficacy, no data exist to guide dose adjustments in obese patients receiving high-dose melphalan. The effects of obesity on dosing changes and their impact on posttransplantation outcomes are important for guiding treatment decisions and further research.
SUBJECTS AND METHODS

Patients
The study population included adult recipients of autologous peripheral blood hematopoietic stem cell transplant for MM between 1995 and 2003 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The study population was limited to patients receiving a melphalan-based conditioning regimen with or without total body irradiation (TBI), and to transplantations done as part of initial therapy, defined as an interval between diagnosis and transplant of #18 months. Planned tandem AutoHCTs were excluded.
Body Mass Index (BMI) and BSA
Obesity was defined according to BMI at the time of transplantation. BMI was calculated as weight (in kg)/height (in m) 2 [25] . Underweight (BMI \ 18.5) patients were excluded from the analysis because of the small sample size (n 5 9) and the likely complicating influence of cancer cachexia because of severe disease. Melphalan doses were reported to the CIBMTR as total mg administered, without specific information as to the treating physician's intended dose per m 2 of BSA or dose modifications for any patient characteristics. We therefore also expressed doses of melphalan as mg/m 2 based on BSA calculated from the height and the actual body weight (ABW) at time of transplantation, using the formula developed by DuBois and DuBois [26] . Alternative BSA calculations were also performed using ideal body weight (IBW; calculated as [height in m] 2 Â 22) [27] and adjusted IBW (calculated as IBW 1 0.25 Â [ABW 2 IBW]).
Definition of Outcomes
Overall survival (OS) from transplantation was defined as the time from date of transplantation to date of death, with survivors censored at the time of last contact. Nonrelapse mortality (NRM) was defined as death occurring in the absence of relapse/progressive disease and summarized by the cumulative incidence estimate with relapse/progression as the competing risk. Relapse/progression was defined as the time to first evidence of progression of myeloma according to the standard European Blood and Marrow Transplant (EBMT)/International Bone Marrow Transplant Registry (IBMTR) criteria [28, 29] and summarized by the cumulative incidence estimate with NRM as the competing risk [29] . Progression-free survival (PFS) was defined as survival without progressive disease or relapse from complete response.
Statistical Analysis
Patient-, disease-, and transplant-related variables were described and compared among the BMI groups using the chi-square statistic for categoric variables and the Kruskal-Wallis test for continuous variables. Univariate probabilities of PFS and OS were estimated using the Kaplan-Meier method with the log-rank test used for univariate comparisons [30] . Univariate probabilities of NRM and relapse/progression were calculated using cumulative incidence curves to accommodate competing risks [31] .
The hazard ratios of the main outcome of interest (BMI subgroups) and other risk factors potentially associated with relapse/progression, treatment failure, and survival were modeled using Cox proportional hazards regression [30, 32] . A stepwise forward/backward model selection approach was used to identify significant risk factors, with the main effect for BMI forced into the model at each step and factors significant at a 5% level kept in the final model. Potential interactions between the main effect and all significant risk factors were tested at the significance level of 0.015, by which criterion a significant interaction was found between the TBI and BMI group for progression and PFS, and borderline (P 5 .012) for OS. Final models for progression, PFS, and OS were therefore constructed including this interaction. Adjusted probabilities of PFS and OS were generated from the final Cox models stratified on the BMI group, and weighted averages of covariate values using the pooled sample proportion as the weight function and were used to estimate likelihood of outcomes in populations with similar prognostic factors. Examination for center effects using a random effects or frailty model found no evidence of a center effect. We compared the factors associated with melphalan dose reduction using logistic regression models and the effect of dose reduction on PFS using Cox proportional hazards models.
Statistical analyses were performed using the statistical package of SAS version 9 (Cary, NC). All P values are 2-sided and reported without adjustment for multiple comparisons.
RESULTS
Study Population
The 1087 patients with MM who met study inclusion criteria included 292 of normal weight, 472 overweight, 198 obese, and 125 severely obese. Median follow-up of survivors was 63 (range: 1-144) months, 61 (3-144) months, 60 (3-133) months, and 59 (3-131) months for the respective BMI categories.
Baseline patient characteristics are shown in Table 1 . Obese patients were younger than their nonobese counterparts. There was a higher prevalence of diabetes among obese patients. Obese transplant recipients also had less frequent hypercalcemia, severe anemia, and renal insufficiency. A higher proportion of severely obese patients were in complete or partial response at time of transplantation.
Outcomes after Autologous Transplantation
In the study population as a whole, there was no clear effect of BMI on PFS, OS, progression, or NRM. We identified a statistically significant interaction between BMI and conditioning regimen for PFS and progression. Among those receiving melphalan alone, there was no clear association between BMI and these outcomes, with PFS at 5 years of 17% of normal weight patients, 18% of overweight patients, 21% of obese patients, and 14% of severely obese patients (P 5 .65). Among those receiving melphalan and TBI, obese and severely obese patients had superior PFS and OS than normal and overweight patients, with PFS at 5 years of 23% in normal weight patients, 17% in overweight patients, 43% in obese patients, and 55% in severely obese patients (P 5 .005). P values for the interactions between BMI and conditioning regimen were highly significant for PFS (P 5 .0063) and progression (P 5 .0085), with borderline significance for OS (P 5 .012), but not significant for NRM (P 5 .43). The effect of BMI on outcomes after transplantation was therefore restricted to patients receiving melphalan with TBI, with obese patients having better outcomes that were mediated primarily through a lower risk of disease progression.
To exclude confounding by baseline imbalances, we constructed multivariable models of PFS, OS, and progression using all potential confounders. These models included each variable individually, in groups of related variables, and in a single model using all variables, none of which showed any evidence of confounding, with no change in the estimate of effect of BMI on outcomes for patients receiving melphalan alone or melphalan with TBI (data not shown). Final multivariable models, constructed using a forward/ backward stepwise algorithm, confirmed the effects of BMI on PFS, progression, and OS, as shown in Tables 2 to 4. A multivariate model for NRM (not shown) showed no evidence of confounding, and BMI did not have any clear effect on this outcome. Estimated probabilities of all these outcomes based on the final multivariate models are shown in Figure 1 .
Effects of Melphalan Dose and Dose Reduction
Doses of melphalan were compared among BMI groups as absolute doses and as doses per m 2 of BSA calculated using ABW, IBW, and adjusted IBW. As expected with BSA-based dosing, patients who were more obese received higher absolute doses of melphalan, both when melphalan was given alone and when it was given in combination with TBI ( Figure 2 ). With both conditioning regimens, patients who were more obese received a lower dose per m 2 of actual BSA (ie, using ABW to calculate BSA). Using IBW or adjusted IBW to calculate BSA resulted in normalized doses that were closer among BMI groups, although there were still significant differences among the groups. When compared on the basis of melphalan dose per kg of body weight [33] , more obese patients received a lower dose of melphalan/kg of ABW.
We further investigated the effect of chemotherapy dosing decisions in obese patients. A full dose of melphalan was defined as 200 mg/m 2 (calculated by ABW) for conditioning regimens using melphalan alone and as 140 mg/m 2 for transplants using melphalan with TBI. A reduced dose of melphalan was defined as\90% of the full dose. Using this definition, reduced doses of melphalan were given to 78% of severely obese, 56% of obese, 32% of overweight, and 11% of normal weight patients (P \ .0001). Therefore, the odds of dose reduction were 30 There was no evidence of an effect of melphalan dose reduction on PFS. Receipt of a reduced dose of melphalan was associated with a univariate hazard ratio for a PFS of 1.07 (95% CI: 0.92-1.23), and in a multivariate analysis (controlling for renal function, performance status, age, race, gender, history of hypertension or diabetes, disease status, and year of transplantation), the hazard ratio associated with melphalan dose reduction was 0.88 (95% CI: 0.70-1.10). We also found no effect of melphalan dose on PFS, regardless of whether the dose was specified as total melphalan administered, as the dose per m 2 of BSA (with, in successive analyses, the BSA calculated using ABW, adjusted IBW, or IBW), or as the dose per kg of ABW. For the absolute dose of melphalan, the hazard ratio associated with a 10-mg increase in dose was 0.99 (95% CI: 0.98-1.01); the hazard ratios per 10 mg/m 2 increase in dose were 1.00 (95% CI: 0.97-1.04), 0.99 (95% CI: 0.96-1.02) and 1.01 (95% CI: 0.99-1.04) when BSA was calculated with actual, adjusted ideal, and IBW, respectively; and the hazard ratio Repeating these analyses in the population of obese and severely obese patients yielded similar results (data not shown). Therefore, none of these analyses showed any effect of variation in chemotherapy dose on PFS.
Dose of TBI
We further investigated the reason for the restriction of the effect of obesity to TBI-containing transplantations. Most patients received a planned dose of 12 Gy (65% of normal and overweight, 74% of obese, and 68% of severely obese patients), with a few patients receiving 13 Gy (9% of normal and 10% of overweight, none of the obese or severely obese), 10-11 Gy (12% of normal, 13% of overweight, 16% of obese, and 23% of severely obese), or \10 Gy; these differences were not significant (overall P value .75). There was no discernible effect of TBI dose on PFS and no evidence that the TBI dose confounded the effect of obesity on PFS (data not shown).
DISCUSSION
We have analyzed a large cohort of patients receiving high-dose melphalan-based AutoHCT for initial therapy of myeloma. We did not find any differences in outcome between obese and nonobese patients receiving a conditioning regimen of single-agent melphalan. This finding suggests that obese patients can receive high-dose melphalan AutoHCT without increased treatment-related mortality and that obesity should not be a contraindication to undergoing autologous transplantation.
Participating transplant centers reported total melphalan doses administered but not information regarding the specific intention of treating physicians in adjusting melphalan doses for individual patients. We therefore do not know which patients received reduced doses based on IBW or adjusted IBW (or with calculated BSA capped to define a maximum allowable dose). Previously published literature suggests that variation in approach to dose adjustment is substantial [34, 35] , and a variety of dosing strategies were likely used in the patients in our study. This is clear from the significant minority of obese patients in our cohort who received doses within 10% of a full dose calculated according to ABW (44% of obese patients and 22% of severely obese patients). Our results suggest that current strategies used in clinical practice for adjusting melphalan doses in obese patients (ie, calculating doses based on ideal or adjusted IBW for some but not all patients) do not appear to impair outcomes in this population. However, our data also confirm previous findings that dosing strategies in obese patients are variable, with a wide range of melphalan doses. Further research to determine optimal dosing for these patients may be helpful in decreasing variability in toxicity and efficacy.
Our results also show that among patients receiving melphalan with TBI, a higher BMI was associated with improved PFS, OS, and risk of progression. The reason for the restriction of a beneficial effect of obesity to the TBI conditioning regimen is unclear. One possible explanation is that the distribution of TBI dose through body tissues differs between obese and thin patients. Standard practice calculates the target radiation dose at the midplane of the body, but deposition of the radiation dose is not uniform, and increasing body size (as measured by anteroposterior distance) requires higher doses delivered to the more superficial tissues to achieve the same midplane dose [36] . Differences in body fat content are generally assumed to have little difference on dose distribution, but it is possible that obese patients' increased size would result in higher doses to the bone marrow, leading to improved antimyeloma efficacy. It is also possible that the metabolism of tumor cells in obese patients differs in a way that makes the cancer more susceptible to radiation, leading to a simple effect of increased radiation efficacy in obese patients. We cannot completely exclude confounding as an explanation for the improved outcomes in obese patients receiving TBI, in that obese transplant recipients may have had less aggressive myeloma or less cancer cachexia in ways not captured by our measured covariates. Such differences would not account for a differential effect restricted to TBI conditioning unless selection of the conditioning regimen at some centers depended on a combination of body size and overall health, so that TBI was offered to healthier obese patients. However, we found no evidence of confounding by any characteristics of the patients, their myelomas, or their therapies, although we were limited by the lack of complete data on some of the newer prognostic factors such as International Stage or beta-2 microglobulin levels. We therefore conclude that further investigation is warranted to fully understand the effect of obesity in the setting of TBI and determine whether delivering therapeutic doses to marrow-containing structures could be further optimized.
The regimen of melphalan and TBI is no longer commonly used for myeloma because of evidence of similar results and less toxicity with melphalan alone [37] . This may limit further investigation into this regimen in the setting of myeloma therapy, but TBI is used in patients with some types of lymphoma and commonly in patients with acute leukemia undergoing allogeneic HCT. Further research will be necessary to determine whether the association between obesity and outcomes applies to these other patient populations, for whom improved targeting of radiation doses could lead to better treatment outcomes.
Our results differ from previously published studies of AutoHCT, but no other study has examined the same specific population. Two studies (in acute myeloid leukemia or lymphoma) have found obesity to be associated with worse posttransplantation outcomes [21, 24] , but analysis of a larger lymphoma cohort from the CIBMTR found no difference in outcomes [23] . Other studies have been limited by the inclusion of multiple diseases, different conditioning regimens, or both autologous and allogeneic transplantations, and have found either no effect of obesity [18] or an increased risk of NRM [19] . None of these trials examined results in patients with myeloma or examined separately outcomes using TBI conditioning regimens, and their results are therefore not directly comparable with the results of our study.
Our study found no evidence that variability in chemotherapy dosing among obese patients leads to differences in outcomes, nor that obese patients are at higher risk of treatment-related mortality or disease progression. In fact, among patients receiving melphalan and TBI, obese patients had a lower risk of relapse. The current commonly used strategy of reducing melphalan doses (calculating based on ideal or adjusted IBW) does not appear to impair outcomes for obese patients, and obesity should not exclude patients from consideration of autologous transplantation. Further research is necessary to optimize dosing of both chemotherapy and radiation in obese patients.
